Medical Device and Diagnostic Industry (MD+DI)

How An FDA Breakthrough Device Could Transform Coronary Care

Elixir Medical's DynamX Bioadaptor restores natural artery function, reducing the risk of future cardiac events.
TCTMD

Elixir Medical Announces DESolve Nx International Pivotal Trial Initiation for Fully Bioresorbable Coronary Scaffold System

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international ...
Business Wire

Elixir Medical Corporation Expands Commercial Operations with Addition of Michele Perrino as President, Commercial and Manufacturing Operations

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that medical device ...
TCTMD

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial for DESyne BD(TM) Novolimus Eluting Coronary Stent with Biodegradable ...
Business Wire

Akesys Medical and Elixir Medical Announce First Human Implant of the PRAVA™ Bioresorbable Scaffold for Peripheral Vascular Disease

SUNNYVALE, Calif.--(BUSINESS WIRE)--Akesys Medical, a drug-device company focused on pioneering innovative solutions for peripheral artery disease, has announced their first clinical trial and ...
FiercePharma

Elixir Medical Receives CE Mark Approval for the DESyne® BD Novolimus Eluting Coronary Stent System With Biodegradable Polymer Coating

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE (Conformité Européenne) Mark ...
FiercePharma

Elixir Medical Announces First Commercial Implant Of The DESolve® Novolimus Eluting Coronary Scaffold System in Europe

SUNNYVALE, Calif.--(BUSINESS WIRE)--Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's ...
Business Insider

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to ...
BioWorld

Items Tagged with 'Elixir Medical Corp.'

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...
Yahoo Finance

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

MILPITAS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced new landmark clinical results for its ...